Compare Incyte Corporation (INCY) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vital Farms Inc — how do they compare? Incyte Corporation trades at $113.14 (market cap $22.85B), while Vital Farms Inc trades at $9.31 (market cap $405.27M). The key difference: Incyte Corporation is far larger — about 56.4× Vital Farms Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vital Farms Inc for 14 Days on average.
| INCY | VITL | |
|---|---|---|
Market Cap | $22.85B | $405.27M |
Volume | 1,927,029 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $43.68 |
52-Week Low | $83.80 | $8.28 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $18.35B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Vital Farms (VITL) trades at $9.45, up 2.27% today, amid a challenging fundamental backdrop. The stock exhibits a bearish technical trend, with recent earnings showing significant pressure on profitability. Revenue for 2025 was $759.44M with a net income of $66.28M, but 2026 projections indicate a sharp decline in net income to near breakeven. Recent news highlights strategic review discussions and institutional investment activity, contributing to volatile price action.
The outlook is mixed; analyst consensus is bullish with a $13.11 price target, but near-term risks from egg pricing pressure and weak profitability metrics pose challenges. Investment opportunity hinges on successful execution of strategic options and margin recovery, while downside risks include sustained industry oversupply and cash flow constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
